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SHORT COMMUNICATION
Immunocytochemical staining of proliferating cells in fine needle
aspiration smears of primary and metastatic breast tumours
V. Kuenen-Boumeesterl, D.I. Blonk1 & Th.H. Van der Kwast2
1Department of Cytology, Rotterdam Radio-Therapeutic Institute, Box 5201, 3008 AE Rotterdam; and 2Department of
Pathology, Erasmus University, Burg. Oudln 50, 3000 DR Rotterdam, The Netherlands
The variability in biological behaviour of breast carcinomas
is a long standing problem. Lymph node status is still the
major prognostic indicator (Fisher et al., 1983), but also
mitotic activity appears to be of considerable prognostic
relevance, either as a single parameter (Schi0dt, 1966;
Stenquist et al., 1981; Baak et al., 1985), or as part of
histological (Bloom & Richardson, 1957; Elston et al., 1982)
or cytological (Mauriquand et al., 1986) grading. Since only
a minor fraction of proliferating cells is in mitosis, the
determination of the total number of proliferating cells could
be a better indicator of the growth fraction of a tumour
population and therefore might give more information about
the biological behaviour of a tumour.
A mouse monoclonal antibody (Ki-67) has become
available defining a nuclear antigen present in proliferating
cells throughout the cell cycle. The antigen is absent in GO
and early GI (Gerdes et al., 1983,1984). Thus, Ki-67 enables
the immunocytochemical detection of cycling cells without
the need of external administration of radioactively labelled
nucleotides or mutagenic substances such as bromo-
deoxyuridine or iododeoxyuridine. Until now studies on
breast tumours using Ki-67 as a proliferation marker were
performed on histological material. As fine needle aspiration
(FNA) smears are more and more used as diagnostic tools,
we investigated the feasibility of the use of this monoclonal
antibody on cytological material obtained from benign and
malignant tumours as well as from distant metastases of
breast carcinomas. In addition, a possible relationship
between the Ki-67 determined growth fraction of breast
carcinomas and clinical parameters such as tumour size,
lymph node status and menopausal status was investigated.
The material consisted of FNA smears of 38 breast
carcinomas (31 invasive ductal, 5 colloid and 2 medullary
carcinomas), 20 fibroadenomas and 26 metastases of breast
carcinomas (16 lymph nodes, 2 liver metastases and 8 local
recurrences); the cellularity of aspirates from metastases and
primary carcinomas was comparable. The air dried smears
were fixed in acetone for 5min and immunostaining with the
mouse monoclonal antibody Ki-67 (Dako, Denmark) diluted
1:10 in PBS, pH7.4, containing 0.05% gelatin and 0.1%
NaN3, was performed using the indirect conjugated
immunoperoxidase method as described previously (Van der
Kwast et al., 1985). After addition of diaminobenzidine as
substrate brown speckled staining of nuclei or nucleoli was
considered as a positive reaction with Ki-67. Mitotic figures
were also stained. Nuclear counterstaining was achieved by a
1 min incubation in Mayer's haematoxylin (Figure 1). The
percentage of Ki-67 positive nuclei was determined by
counting 500 cells at a magnification of 1000 x. The
counting was done by a cytologist (VK) and care was taken
to count tumour cells only or in the case of benign tumours
to count breast epithelial cells only. The clinical data
collected from the patients with the primary tumours are
shown in Table I.
Figure 1 Picture of FNA smear of breast carcinoma, showing
Ki-67 stained nuclei (arrows).
Table I Clinical data of 38 patients with primary breast carcinomas
Premeno Postmeno 1? TI T2 T3 T4 N? NO NI N2
10 28 2 11 18 3 4 3 14 11 10
Total 38
T? =Unknown; N? =Unknown.
38 38
The FNA smears of the benign tumours contained a low
percentage of immunostained nuclei, ranging from 0.0-6.7
with a mean of 1.1 and a median of 0.4. In contrast only
four of the malignant tumours showed a percentage below 2,
21 between 2 and 10 and 13 even higher than this (Figure 2)
with a mean of 10.5 and a median of 7.9. In comparison
with the malignant primary tumours the metastases revealed
even higher values with a mean of 14.3 and a median
percentage of 12.3. The difference of the last two median
values, assessed by the Whitney-test was statistically
significant (P<0.05).
Assessment of the Ki-67 determined proliferative tumour
cell fraction in FNA smears of malignant breast lesions led
to essentially similar results as recently reported in several
studies (Gerdes et al., 1986; Lelle et al., 1987; McGurrin et
al., 1987; Barnard et al., 1987) of Ki-67 determination on
cryostat sections of breast tumours (Table II). It appears
from the data in Table II that the Ki-67 percentages of
cryostat sections tend to be higher than those of the
aspirates. This lower figure in aspirates may be explained by
sampling differences. When the tumour is aspirated the
material is derived from both peripheral and central parts of
the tumour, whereas a cryostat section gives information on
one part of the tumour only.
According to Baak et al. (1985) and Van der Linden et al.
(1987) the mitotic activity index in histological material is
the strongest independent prognostic factor in their group of
patients both retrospectively and prospectively. Although the
prognostic significance of the Ki-67 determined proliferative
tumour cell fraction remains to be proven, we think that
determination of the total cycling fraction of a tumour gives
more information about prognosis than assessment of
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Figure 2 The percentages of Ki-67 stained nuclei in benign,
malignant and metastatic breast tumours. A=benign (n =20);
B =malignant (n=38); and C =metastases (n =26). Arrow
signifies median.
Table II Reported data of mean percentages of
Ki-67 stained nuclei in primary breast carcinomas
in cryostat sections and imprints/FNA smears
Histology Cytology
Gerdes 16.6
Lelle 16.2 14.5a
McGurrin 22.0
Barnard 20.6
This study 10.5b
aImprints; bFNA smears.
overestimation of the fraction of actually proliferating cells.
In contrast to the findings of Lelle et al. (1987), but in
agreement with the study of McGurrin et al. (1987) and
Barnard et al. (1987), we found no relation between lymph
node status and percentage of Ki-67 labelled tumour cells.
Neither did the 3H-thymidine labelling studies (Meyer et al.,
1983; Tubiana et al., 1984) show any relation to lymph node
status.
No clear-cut correlation was found in this study between
tumour size and menopausal status or percentage of Ki-67
immunostained nuclei. Probably the number of investigated
tumours was too low to establish such a relationship. It was
interesting to see, however, that the really high values (above
40%, see Figure 3) were only seen in premenopausal women.
In addition, the two highest values (30.5% and 19%) in
the group of postmenopausal women were medullary
carcinomas. It is known that the latter tumours have a high
mitotic activity and display a different biological behaviour
than the infiltrating duct carcinomas (Azzopardi, 1979).
Our observation of significantly higher percentages of Ki-
67 labelled tumour cells in metastases compared to primary
carcinomas may point to two possibilities: tumours with a
higher proliferative activity may tend to a more aggressive
biological behaviour, or the higher proliferative activity of
metastasized tumour cells is caused by a more favourable
environment. In support of the first possibility is the
prospective study of Tubiana et al. (1984) which showed that
the 3H-thymidine labelling index is related to the probability
of metastatic dissemination. In addition, Meyer et al. (1983)
showed that the 3H-thymidine labelling index of primary
breast tumours and their corresponding axillary metastases
were not significantly different. Thus, it seems unlikely that
the higher proliferative activity of metastasized tumours can
be attributed to microenvironmental influences. Nevertheless,
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numbers of mitotic figures alone. This holds especially true
for FNA smears, since they rarely contain mitotic tumour
cells. Further support for the hypothesis that the Ki-67
determined proliferative fraction may be of prognostic
relevance can be drawn from the in vitro 3H-thymidine
labelling studies of Meyer et al. (1983) and Tubiana et al.
(1984). These authors incubated small specimens of freshly
obtained breast tumour tissue with 3H-thymidine and
counted the number of labelled nuclei from autoradio-
graphed microscopic sections. In the study of Meyer et al.
(1983) with a follow-up period of 4 years both the lymph
node status and the 3H-thymidine labelling index appeared
to be the strongest independent indicators of early relapse.
In the long-term prospective study of Tubiana et al. (1984)
the 3H-thymidine labelling index appeared to be the most
predictive independent indicator with respect to relapse-free
survival and total survival. It should be noted that Ki-67
immunostaining is only indirect evidence of proliferation
while the mitotic index and 3H-thymidine incorporation
directly relate to proliferative activity. Furthermore, Ki-67
stains cells in GI-phase, cells arrested in this phase of the
cell cycle may also be stained by Ki-67 which leads to an
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Figure 3 Percentage of Ki-67 stained nuclei of the primary
carcinomas versus menopausal status. M=medullary carcinoma.
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it would be interesting to compare the Ki-67 immunostaining
results of the aspirates of the primary tumours and the
metastases from the same patient.
Further studies are indicated to demonstrate the
prognostic relevance of the immunocytochemical assessment
of Ki-67 determined proliferative fraction of tumour cells in
FNA smears.
We wish to express our gratitude to Miss C. Trappenburg and to
A.C.M. van Nispen for their technical assistance.
References
AZZOPARDI, J.G. (1979). Problems in breast pathology. Major
problems in pathology, p. 288. W.B. Saunders: Philadelphia.
BAAK, J.P.A., VAN DOP, H., KURVER, P.H.J. & HERMANS, J. (1985).
The value of morphometry to classic prognosticators in breast
cancer. Cancer, 56, 374.
BARNARD, N.J., HALL, P.A., LEMOINE, N.R. & KADAR, N. (1987).
Proliferative index in breast carcinoma determined in situ by
Ki-67 immunostaining and its relationship to clinical and
pathological variables. J. Pathol., 152, 287.
BLOOM, H.J.G. & RICHARDSON, W.W. (1957). Histological grading
and prognosis in breast cancer: A study of 1409 cases of which
359 have been followed for 15 years. Br. J. Cancer, 11, 359.
ELSTON, C.W., GRESHAM, G.A., RAO, G.S. & 4 others (1982). The
cancer research campaign (King's/Cambridge) trial for early
breast cancer: Clinico-pathological aspects. Br. J. Cancer, 45,
655.
FISHER, B., BAUER, M., WICKERHAM, D.L., REDMOND, C.K.,
FISHER, E.R. & cooperating investigators. (1983). Relation of
number of positive axillary nodes to the prognosis of patients
with primary breast cancer. Cancer, 52, 1551.
GERDES, J., SCHWAB, U., LEMKE, H. & STEIN, H. (1983).
Production of a mouse monoclonal antibody reactive with a
human nuclear antigen associated with cell proliferation. Int. J.
Cancer, 31, 13.
GERDES, J., LEMKE, H., BAISCH, H., WACKER, H.H., SCHWAB, U. &
STEIN, H. (1984). Cell cycle analysis of a cell proliferation-
associated human nuclear antigen defined by the monoclonal
antibody Ki-67. J. Immunol., 133, 1710.
GERDES, J., LELLE, R.J., PICKARTZ, H. & 5 others (1986). Growth
fractions in breast cancers determined in situ with monoclonal
antibody Ki-67. J. Clin. Pathol., 39, 977.
LELLE, R.J., HEIDENREICH, W., STAUCH, G. & GERDES, J. (1987).
The correlation of growth fractions with histologic grading and
lymph node status in human mammary carcinoma. Cancer, 59,
83.
McGURRIN, J.F., DORIA, M.I., DAWSON, P.J. & 4 others (1987).
Assessment of tumour cell kinetics by immunohistochemistry in
carcinoma of breast. Cancer, 59, 1744.
MEYER, J.S., FRIEDMAN, E., McCRATE, M.M. & BAUER, W.C.
(1983). Prediction of early course of breast carcinoma by
thymidine labelling. Cancer, 51, 1879.
MOURIQUAND, J., GOZLAN-FIOR, M., VILLEMAIN, D. & 4 others
(1986). Value of cytoprognostic classification in breast
carcinomas. J. Clin. Pathol., 39, 489.
SCHI0DT, T. (1966). Breast carcinoma. A histologic and prognostic
study of 650 followed-up cases. Ejnar Munksgaard, Copenhagen.
STENKVIST, B., BENGTSSON, E., ERIKSSON, O., JARKRANS, T.,
NORDIN, B. & WESTMAN-NAESER, S. (1981). Correlation
between cytometric features and mitotic frequency in human
breast carcinoma. Cytometry, 1, 287.
TUBIANA, M., PEJOVIC, M.H., CHAVAUDRA, N., CONTESSO, G. &
MALAISE, E.P. (1984). The long term prognostic significance of
the thymidine labelling index in breast cancer. Int. J. Cancer, 33,
441.
VAN DER KWAST, TH.H., VAN VLIET, E., CRISTEN, E., VAN EWIJK, W.
& VAN DER HEUL, R.O. (1985). An immunohistologic study of the
epithelial and lymphoid components of six thymomas. Human.
Pathol., 16, 1001.
VAN DER LINDEN, J.C., BAAK, J.P.A., LINDEMAN, J., HERMANS, J.
& MEYER, C.J.L.M. (1987). Prospective evaluation of prognostic
value of morphometry in patients with primary breast cancer. J.
Clin. Pathol., 40, 302.